Edward Dolk
Utrecht, UT, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
The development of single-domain VHH nanobodies that target the Candida albicans cell surface.
Journal: Microbiology spectrum
Published: October 07, 2024
Nanobody-mediated neutralization of candidalysin prevents epithelial damage and inflammatory responses that drive vulvovaginal candidiasis pathogenesis.
Journal: mBio
Published: February 13, 2024
Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodies.
Journal: The Journal of biological chemistry
Published: March 06, 2023
Candidalysin Is the Hemolytic Factor of Candida albicans.
Journal: Toxins
Published: November 21, 2022
Recombinant Limosilactobacillus (Lactobacillus) delivering nanobodies against Clostridium perfringens NetB and alpha toxin confers potential protection from necrotic enteritis.
Journal: MicrobiologyOpen
Published: December 28, 2021
Legomedicine-A Versatile Chemo-Enzymatic Approach for the Preparation of Targeted Dual-Labeled Llama Antibody-Nanoparticle Conjugates.
Journal: Bioconjugate chemistry
Published: January 04, 2017
Effective Inhibition of Bone Morphogenetic Protein Function by Highly Specific Llama-Derived Antibodies.
Journal: Molecular cancer therapeutics
Published: November 10, 2014
Selection of VHHs under application conditions.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: August 14, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026